BMO Capital Starts Regulus Therapeutics (RGLS) at Outperform
Tweet
Share
E-mailGet Alerts RGLS Hot Sheet
Price: $8.16 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
BMO Capital initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform. PT $10.00.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $5.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Benchmark Resumes MACOM Technology Solutions (MTSI) at Buy
- Fubon Assumes Hon Hai Precision Industry Co Ltd. (2317:TT) (HNHPD) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
